This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, including efficacy and safety, of esketamine treatment. It also explores predictors of treatment response, focusing on biological pathways such as genetics, neuroimaging, and psychophysical measures. Additionally, the study examines how esketamine impacts patients' life functioning, including social and occupational aspects. The goal is to better understand who benefits most from esketamine and how it affects daily life, to improve personalized care for patients with difficult-to-treat depression.
Study Type
OBSERVATIONAL
Enrollment
100
Esketamine Intranasal Spray at a dosage ranging from 28 to 84 mg weekly, with twice-weekly administration during the first month of treatment, according to the approved labeling
Ospedale Policlinico San Martino
Genova, Ge, Italy
RECRUITINGCsm Dds 8
Genova, Ge, Italy
RECRUITINGUniversità di Chieti
Chieti, Italy
RECRUITINGASST Fatebenefratelli Sacco
Milan, Italy
RECRUITINGASST Pavia
Pavia, Italy
RECRUITINGPredictive Factors of Treatment Response: Biological, Clinical, and Social Dimensions
MADRS, HAM-D, HAM-A, TCI-R, BPRS, AES, SHAPS, EQ-5D-5L, BDI-II, WPAI-D, SDS, TEMPS
Time frame: Time Frame: from enrollment to one year of treatment
Panel of genetic polymorphisms (SNPs) predictive of clinical response to esketamine in patients with treatment-resistant depression.
Time frame: from enrollment to one year of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.